Description
**PT-141 Research Overview**
—
**1. What it does**
PT-141 (Bremelanotide) is a synthetic peptide developed from the melanocortin receptor agonist family. Unlike other sexual dysfunction treatments that primarily target the vascular system, PT-141 acts directly on the nervous system to stimulate sexual arousal. It affects the melanocortin receptors in the brain, influencing sexual desire and motivation.
—
**2. What are the main reported benefits**
– Increased sexual desire and libido in both men and women
– Improved sexual satisfaction
– Treatment for erectile dysfunction (ED) in men
– Treatment for hypoactive sexual desire disorder (HSDD) in women
– Enhanced sexual spontaneity (effects not solely dependent on sexual stimulation)
—
**3. What are its normal applications**
– Research and clinical use for sexual dysfunction
– Investigational treatment for low sexual desire disorders
– Studies examining central nervous system mechanisms for sexual function
*Note:* PT-141 (as Bremelanotide) is FDA-approved under the brand name Vyleesi for HSDD in premenopausal women.
—
**4. What are its common side effects**
– Nausea (most common)
– Flushing and facial redness
– Headache
– Increased blood pressure (transient)
– Injection site reactions
– Possible darkening of skin (hyperpigmentation) with prolonged use
Most side effects are transient and resolve without intervention.
—
**5. What is the recommended administration or dosage**
– **Typical Dosage**: 1.25 mg to 2.25 mg administered as needed prior to anticipated sexual activity
– **Administration Route**: Subcutaneous injection (usually into the abdomen or thigh)
**Timing:**
– Administer approximately 45 minutes before sexual activity.
– Recommended use is no more than once every 24 hours and no more than 8 doses per month.
**Preparation:**
– PT-141 is available as a prefilled autoinjector for approved use, or as a lyophilized powder for research purposes that must be reconstituted with bacteriostatic water.
—
